Fee schedule: Average sales price data for new drug payment formula could be the culprit in holding up proposed 2005 fee schedule

Article Overview

This article discusses a delay in the release of the proposed physician fee schedule and the role of average sales price data reported by drug manufacturers in CMS’s process. It is relevant to physicians, coders, billing staff, and reimbursement professionals who track Medicare physician payment updates, especially for office-administered Part B drugs and annual fee schedule changes. The article also references the Medicare Prescription Drug Improvement and Modernization Act and the timing of prior proposed fee schedule publications.